News
A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...
The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.
The drug, which Repare recently sidelined, has shown promising activity in a patient with ALT-positive melanoma that researchers want to study in others.
NEW YORK – CAR T-cell therapy developer Cargo Therapeutics earlier this week announced it will be bought by Concentra Biosciences.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results